Foresee Pharmaceuticals is focused on advancing innovative biopharmaceutical technologies, particularly through its proprietary Stabilized Injectable Formulation (SIF) technology. This platform enables the development of long-acting injectable (LAI) therapies that provide sustained drug release, enhancing patient compliance and treatment efficacy. The SIF technology is exemplified by the company's leuprolide injectable emulsion, marketed as CAMCEVI, which is currently approved for treating advanced prostate cancer and is undergoing clinical trials for central precocious puberty (CPP). The favorable safety profile and efficacy demonstrated in ongoing studies highlight the potential of SIF technology to address significant unmet medical needs in various therapeutic areas.

In addition to SIF, Foresee Pharmaceuticals is also dedicated to developing New Chemical Entities (NCEs) targeting rare and severe diseases. Their pipeline includes several promising candidates, such as Aderamastat, a selective oral MMP-12 inhibitor for inflammatory and fibrotic diseases, and Mirivadelgat, an allosteric activator of ALDH2 for conditions like pulmonary hypertension. These innovative approaches reflect Foresee's commitment to pioneering treatments that improve patient quality of life and address critical health challenges globally. The company's strategic focus on both SIF and NCEs positions it as a key player in the biopharmaceutical landscape, aiming to deliver transformative therapies to patients in need.

United States

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Stock Exchange. The company engages in the pharmaceutical sector and focuses on developing innovative drugs for various medical conditions such as prostate cancer, asthma, and COPD. Foresee Pharmaceuticals has a diverse set of clinical and development candidates with distinct profiles and patents.

Foresee Pharmaceuticals

Company Details